Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?

CEO Craig Wheeler talked to Scrip about the challenging biosimilar market dynamics and the company's decision to end most biosimilar drug development. The path to value creation in biosimilars is not clear, he said.